| Popis: |
Background: Obese-related asthma (OBA) is an asthma sub-phenotype that often is severe. Inflamed adipose tissue may release pro (leptin) and anti-inflammatory (adiponectin) adipokines implicated in OBA. The effects of treatment with oral corticosteroids (OCS) on systemic levels of adipokines remains unknown. Subjects and Methods: Patients with mild to moderate asthma (MMA, n=55), severe asthma (SA= 72) and COPD (n=41) were from BIOAIR, a European multicenter study. After recruitment (visit 1), patients were optimized with medium doses of inhaled glucocorticosteroids (ICS) and LABA for four weeks (visit 2), then included in a double blind placebo-controlled OCS intervention trial (visit 3A), followed by an open OCS treatment in the placebo group (visit 3B). Blood samples were collected for measurement of leptin and adiponectin. Results: At visit 1, leptin was higher in SA compared with MMA (p = 0.0085) and COPD (p = 0.0006). Both leptin and adiponectin were significantly higher in women than in men. A positive correlation between leptin and higher BMI was found for both sexes in all groups and a negative correlation between adiponectin and BMI in COPD and male SA. No correlation was found in female SA and MMA. Optimization did not significantly change neither leptin nor adiponectin. OCS intervention resulted in increases in leptin (MMA p = 0.029; SA p = 0.0010; COPD p = 0.0004) and adiponectin (MMA p = Conclusions: OCS increased systemic levels of leptin and adiponectin in patients with asthma and COPD. |
